Frontline immunotherapy for NSCLC: alone or not alone?

Frontline immunotherapy for NSCLC: alone or not alone?Frontline immunotherapy for NSCLC: alone or not alone?, Published online: 11 July 2018; doi:10.1038/s41571-018-0070-7Platinum-based chemotherapy has long been the mainstay first-line therapy for patients with non-small-cell lung cancer without a targetable driver mutation, but has limited effectiveness. Immunotherapy is drastically changing the treatment landscape for this group and improving survival outcomes, with focus turning to frontline immunotherapy combinations.

Source: Nature Clinical Practice Oncology - July 11, 2018 Category: Cancer & Oncology Authors: Cesare Gridelli Francesca Casaluce Source Type: research